Receive our newsletter – data, insights and analysis delivered to you
July 1, 2009

Vical H1N1 Flu Vaccine Scores 100% in Preclinical Trials

Biopharmaceutical company Vical has announced plans to start large-scale manufacturing of its H1N1 influenza vaccine after the vaccine showed a response rate of 100% during preclinical testing. The study enrolled mice and rabbits, where the subjects were vaccinated with a standard two-do

By cms admin

Biopharmaceutical company Vical has announced plans to start large-scale manufacturing of its H1N1 influenza vaccine after the vaccine showed a response rate of 100% during preclinical testing.

The study enrolled mice and rabbits, where the subjects were vaccinated with a standard two-dose vaccine regimen.

During the testing at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of the vaccine.

Vical president and CEO Vijay Samant said that the speed of the platform in development and manufacturing was demonstrated by rapid completion of vaccine production and successful immunogenicity testing in animals.

“While conventional vaccine manufacturers are still working toward production of their initial supply of H1 vaccine, we are encouraged by these compelling data with our Vaxfectin-formulated DNA vaccine and we look forward to advancing to human clinical trials as soon as possible,” Samant said.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU